| PROJECT | CENTERS / COUNTRIES | WEST EUROPE | EST EUROPE | LATIN AMERICA | NORTH AMERICA | OTHERS | TOTALS |
| CEST | 1 / 1 | 6 | 0 | 0 | 0 | 0 | 6 |
| Kawasaki Disease IVIg resistance scores | 4 / 3 | 134 | 5 | 0 | 0 | 1 | 140 |
| HyperPED-COVID | 49 / 22 | 369 | 191 | 173 | 0 | 99 | 832 |
| LoSQI validation | 1 / 1 | 10 | 0 | 0 | 0 | 0 | 10 |
| DAISY | 6 / 5 | 30 | 27 | 0 | 0 | 0 | 57 |
| The STARS trial | 18 / 1 | 144 | 0 | 0 | 0 | 0 | 144 |
| JIA classification | 96 / 32 | 914 | 375 | 35 | 103 | 80 | 1507 |
| INSAID registry | 3 / 3 | 28 | 0 | 0 | 0 | 0 | 28 |
| MAS | 90 / 31 | 620 | 138 | 74 | 148 | 131 | 1111 |
| ABIRISK Registry | 24 / 12 | 69 | 86 | 0 | 0 | 0 | 155 |
| EUROFEVER | 118 / 41 | 3958 | 706 | 73 | 16 | 233 | 4986 |
| PHARMACHILD | 86 / 31 | 5304 | 2881 | 752 | 0 | 275 | 9212 |
| EPOCA | 118 / 49 | 5517 | 4036 | 1313 | 773 | 2175 | 13814 |
| JDM Trial | 53 / 20 | 86 | 12 | 34 | 6 | 0 | 138 |
| MTX Withdrawal | 61 / 29 | 178 | 93 | 80 | 0 | 13 | 364 |
| Vasculitis | 93 / 36 | 916 | 159 | 233 | 6 | 85 | 1399 |
| Antares | 16 / 1 | 213 | 0 | 0 | 0 | 0 | 213 |
| CSA | 56 / 22 | 183 | 50 | 25 | 85 | 1 | 344 |
| JDM CS | 95 / 36 | 160 | 37 | 78 | 17 | 3 | 295 |
| JSLE CS | 108 / 39 | 258 | 93 | 150 | 35 | 21 | 557 |
| CHAQ CHQ Healthy | 32 / 32 | 2115 | 575 | 524 | 0 | 195 | 3409 |
| CHAQ CHQ JIA | 32 / 32 | 2019 | 696 | 379 | 0 | 141 | 3235 |
| MTX Pavia | 56 / 20 | 518 | 39 | 66 | 8 | 2 | 633 |
| TOTAL | 220 / 54 | 23749 | 10199 | 3989 | 1197 | 3455 | 42589 |